Waldenström Macroglobulinemia | Tumor

Bexobrutideg Receives Orphan Drug Designation in Waldenström Macroglobulinemia

March 17th 2025, 7:00pm

Article

Bexobrutideg, a bioavailable agent, was granted orphan drug designation by the FDA for Waldenström macroglobulinemia, a type of non-Hodgkin's lymphoma.

FDA Grants Fast Track Designation to NX-5948 for R/R WM

December 30th 2024, 2:00pm

Article

NX-5948 has received fast track designation for adults with relapsed or refractory Waldenström macroglobulinemia who received at least two prior lines of therapy.

‘Golden Bachelor’ Reveals Cancer Diagnosis, Ryne Sandberg’s Cancer Has Returned and More

December 13th 2024, 4:00pm

Article

From Gerry Turner announcing he has cancer to the return of a Chicago Cubs legend’s disease, here’s what’s happening in the cancer space this week.

Heart Risk May Occur Less With Some BTK Inhibitors in B-Cell Blood Cancers

December 9th 2024, 11:00pm

Article

In patients with certain B-cell blood cancers, heart-related side effects may occur less after receiving second-generation BTK inhibitors.

Iopofosine I 131 Is Promising Across Waldenstrom’s Macroglobulinemia Types

July 24th 2024, 3:00pm

Article

Eighty percent of patients with relapsed or refractory Waldenstrom’s macroglobulinemia responded to treatment with iopofosine I 131, researchers found.

FDA Approves Easier-to-Swallow Imbruvica Formulation

February 29th 2024, 10:00pm

Article

An oral suspension formula of Imbruvica received the green light from the Food and Drug Administration to be used in all approved indications.

FDA Gives Cancer Drug Updates, Prostate Cancer Trial Enrolls Patients

January 15th 2024, 4:00pm

Podcast

Last week, the FDA provided updates on two cancer therapies. In this episode, we discuss those decisions and more.

Novel Drug Shows 100% Disease Control Rate in WM

January 9th 2024, 4:00pm

Article

A small study of iopofosine I 131 in patients with pretreated Waldenstrom’s macroglobulinemia showed that the disease control rate was 100%.

FDA Lifts Partial Hold on Trial Investigating Emavusertib in Lymphoma

August 19th 2022, 7:00pm

Article

The FDA has allowed the manufacturer of emavusertib to continue a phase 1/2 study investigating effects of the treatment in patients with lymphoma.

FDA Grants Orphan Drug Designation to Novel CAR-T Cell Therapy to Treat Waldenstrom Macroglobulinemia, a Rare Type of Cancer

June 27th 2022, 9:00pm

Article

Treatment with the novel CAR-T cell therapy was associated with favorable efficacy and safety results in a group of patients with follicular lymphoma, including a few with Waldenstrom macroglobulinemia, according to findings from a study presented at a recent medical conference.